Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COPD muscle loss mystery: new study probes hidden factors

NCT ID NCT07509528

Knowledge-focused Sponsor: Hacettepe University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explored why some people with COPD lose muscle mass and strength (sarcopenia). Researchers measured exercise ability, frailty, and breathing in 42 adults with COPD. The goal was to find which factors most affect muscle loss, helping guide future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

42 people

The number who actually took part.

Started

Jun 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will be conducted with COPD patients referred to the Physical Therapy and Rehabilitation Department of Bursa City Hospital for cardiopulmonary rehabilitation. For sample size analysis, the study by Tsekoura et al., which examined the prevalence of sarcopenia and factors affecting sarcopenia among COPD patients, was used. Sample size analysis was performed using the SCALEX SP program (Heinrich Heine University, Düsseldorf, Germany). Based on the frailty prevalence (24.6%) in the study by Tsekoura et al., and considering the 20% patient mortality rate, at least 41 COPD patients need to be included in the study to reach the required significance level of 0.05.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals who were clinically stable for the past month and not using antibiotics, * 40 years of age and older, cooperative, able to ambulate without support or assistive devices, * diagnosed with and followed up at the Chest Diseases Outpatient Clinic of Bursa City Hospital, * evaluated for sarcopenia by an internal medicine and geriatrics specialist, and volunteered to participate in the study were included. Exclusion Criteria: * Individuals with any additional neuromuscular, musculoskeletal, cardiac, rheumatological, neurological, psychiatric or orthopedic disease, * other chronic diseases that may affect balance and walking, * cognitive impairment (Mini Mental Test score \<24) (13) were not included in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (chronic obstructive pulmonary disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset Frailty Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (chronic obstructive pulmonary disease) Frailty Sarcopenia

Contacts and locations

Locations

  • Bursa City Hospital

    Bursa, 16250, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.